Gerresheimer’s June Reckoning Nears as Share Rally Loses Steam

Gerresheimer's rally stalls as accounting irregularities force withdrawal of 2024 results, AGM postponed; restated audit due June, institutional investors trim stakes.

The glass and packaging specialist Gerresheimer finds itself caught between a sharp technical recovery and a deepening credibility gap over its financial reporting. While the stock has more than doubled from February’s nadir of 15.57 euros, the rally is fraying as investors refocus on the accounting irregularities that forced the withdrawal of the 2024 audited results and pushed back the annual general meeting indefinitely.

After touching a six-month high mid-week, the shares reversed course, closing Friday at 24.84 euros — down 1.43% from the prior session’s 25.20 euros. That still leaves the stock up 40.66% over the past month, though the year-to-date picture remains bleak with a 60.10% decline. The Relative Strength Index of 28.1 signals short-term selling pressure is building, and the 200-day moving average continues to trade above the current price, suggesting the long-term downtrend is far from broken.

The root cause of the market’s unease lies in a pair of balance-sheet bombshells. Internal reviews uncovered irregularities in revenue recognition and inventory valuation, pointing to potential write-offs of 220 million to 240 million euros. Those findings forced Gerresheimer to withdraw its audited 2024 accounts in February, and a restated filing is now expected in June — a deadline that will test the credibility of the entire turnaround narrative. An additional special audit by a second accounting firm is also underway.

The postponement of Gerresheimer’s ordinary annual general meeting, originally scheduled for early June, underscores how far the company is from restoring normal governance. Management has declined to set a new date until “reliable data” is available, prolonging the period of opacity. Interim CEO Uwe Röhrhoff has been shoring up support from lenders, who have signaled continued backing, but the absence of a signed-off financial statement leaves the company’s real leverage and cash position uncertain.

Institutional investors are beginning to adjust their exposure. Goldman Sachs notified the market on May 7 that its total stake had dipped from 20.13% to 19.80% of voting rights. While the reduction is modest in absolute terms, any movement by a top shareholder in such a fragile environment is amplified. Analysts remain broadly bearish: UBS downgraded the stock to Sell, DZ Bank reiterated its negative stance, and the consensus price target of 24.04 euros hovers almost exactly at the current trading level.

Operationally, Gerresheimer is betting on its Medical Devices segment and biopharma solutions to offset lingering inventory destocking in the glass business. The acquisition of Bormioli Pharma is expected to lift revenue and profitability over time. But until the June audit provides clarity on both the historical accounting and the balance-sheet impact of that deal, these growth ambitions will remain subordinate to the immediate question of whether the company can deliver a clean set of numbers. The next few weeks will determine whether the recent share recovery was a genuine inflection point or just a dead-cat bounce.